Morphine Dosing for Neonatal Opioid Withdrawal Syndrome (NOWS)
For newborns with opioid dependence from prenatal exposure, initiate oral morphine at 0.3–1.0 mg/kg/day divided every 3–4 hours, with PRN doses of 0.03–0.05 mg/kg every 3–4 hours as needed for breakthrough symptoms, then wean by 10% daily once symptoms are controlled down to 10–20% of maximum dose before discontinuation. 1
Initial Dosing Strategy
The 2024 AAP guidelines provide the most current framework for morphine dosing in NOWS 1:
- Starting dose: 0.3–1.0 mg/kg/day orally, divided into doses every 3–4 hours
- PRN (as-needed) dosing: 0.03–0.05 mg/kg per dose every 3–4 hours for inadequate symptom control
- Dose escalation: Increase by 25% every 24 hours if symptoms persist (maximum 1 mg/kg/day per protocol) 1
Weight-based dosing appears superior to symptom-based titration alone, as it achieves symptom control faster with fewer escalation steps and reduces the need for adjunctive medications 2. Starting with adequate initial dosing prevents prolonged escalation phases that extend hospitalization.
Titration and Maximum Dose
Monitor withdrawal symptoms using standardized scoring (Finnegan scale). Titrate upward if:
- Three consecutive elevated scores indicate inadequate control
- Symptoms worsen despite current dosing
Maximum dose: 1.0 mg/kg/day is the typical ceiling 1, though some protocols allow higher doses in severe cases. Once symptoms stabilize for 24–48 hours at a given dose, begin weaning.
Weaning Protocol
Standard wean: Reduce by 10% of the maximum dose daily once symptoms are controlled 1. Continue this reduction until reaching 10–20% of the peak dose, then discontinue. This typically results in:
Key principle: Wean slowly enough to prevent withdrawal recurrence but rapidly enough to minimize opioid exposure. If withdrawal symptoms re-emerge during weaning, pause the taper or increase back to the previous effective dose, then resume weaning more gradually 5.
Critical Considerations
Morphine vs. alternatives: While morphine remains widely used, recent evidence suggests:
- Methadone may reduce length of stay compared to morphine in several RCTs 1
- Buprenorphine shows promise with shorter hospitalizations in single-site studies 1
- Clonidine as monotherapy resulted in shorter treatment duration (28 vs 39 days) and better neurobehavioral outcomes compared to morphine 3
However, morphine's shorter half-life allows more precise symptom-based dosing adjustments 1, making it appropriate when frequent dose titration is anticipated.
Adjunctive therapy: If morphine alone at maximum dose fails to control symptoms, add:
- Phenobarbital (loading 10–20 mg/kg, maintenance 5–8 mg/kg/day) - associated with shorter hospitalization but longer total medication exposure due to prolonged outpatient weaning 1
- Clonidine (1 mcg/kg every 4 hours) - no neurodevelopmental risk but requires blood pressure/heart rate monitoring 1
Common pitfalls to avoid:
- Starting with inadequate initial doses, leading to prolonged escalation phases
- Abrupt discontinuation rather than gradual weaning - this causes severe withdrawal, uncontrolled symptoms, and potential complications 5
- Failing to use standardized protocols - protocolized dosing and weaning improves outcomes 1
- Overlooking nonpharmacologic interventions (rooming-in, breastfeeding if appropriate, swaddling, reduced stimulation) which should be maximized before initiating pharmacotherapy 1
Monitoring: Assess frequently for withdrawal symptoms (irritability, tremor, high-pitched cry, poor feeding, diarrhea, tachypnea) and adverse effects (excessive sedation, respiratory depression). The Finnegan scoring system guides dose adjustments in most protocols 1.
Special populations: Extremely premature infants may require higher doses for longer durations due to immature drug metabolism 6. Polysubstance exposure (especially benzodiazepines) often necessitates adjunctive phenobarbital 1.